Reminder for Mereo BioPharma Class Action Participation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MREO?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while the studies failed to meet primary endpoints, leading investors to purchase ADS at inflated prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel, avoiding inexperienced intermediaries, to ensure effective legal representation and support in the class action process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.336
Low
0.50
Averages
2.08
High
5.00
Current: 0.336
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Mereo BioPharma Class Action Participation
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while the studies failed to meet primary endpoints, leading investors to purchase ADS at inflated prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel, avoiding inexperienced intermediaries, to ensure effective legal representation and support in the class action process.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc should note that the deadline to join the class action for American Depositary Shares purchased between June 5, 2023, and December 26, 2025, is April 6, 2026, and failure to act may result in losing the opportunity to serve as lead plaintiff.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby minimizing the financial risk associated with joining the class action.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma provided misleading positive statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab, leading investors to purchase shares at artificially inflated prices, which ultimately resulted in financial losses when the true results were disclosed, highlighting significant deficiencies in the company's information disclosure practices.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has a proven track record, having recovered over $438 million for investors in 2019 alone, indicating their substantial experience and capability in handling such cases, which is crucial for investors when selecting legal representation.
See More
Faruqi & Faruqi Investigates Mereo BioPharma Securities Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities claims against Mereo BioPharma, specifically urging investors who purchased securities between June 5, 2023, and December 26, 2025, to contact them before the April 6, 2026 deadline to seek lead plaintiff status.
- Lawsuit Allegations: The lawsuit alleges that Mereo BioPharma and its executives violated federal securities laws by failing to disclose the true status of the Phase 3 ORBIT and COSMIC programs, leading to investor misconceptions about the company's prospects.
- Stock Price Plunge: On December 29, 2025, Mereo BioPharma announced that its two Phase 3 studies failed to meet primary endpoints, resulting in an 87.64% drop in stock price to $0.28 per share, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Faruq & Faruqi LLP encourages anyone with information regarding Mereo BioPharma's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for investor protection.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares during the class period from June 5, 2023, to December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations: The complaint alleges that Mereo BioPharma provided overly positive statements about its Phase 3 ORBIT and COSMIC programs while concealing significant adverse facts, misleading investors about the true state of these clinical trials.
- Stock Price Collapse: Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Next Steps for Shareholders: Shareholders must register by April 6, 2026, to participate in the class action, and upon registration, they will receive updates on the case's progress without any cost or obligation to participate.
See More
JP Morgan Downgrades Mereo BioPharma Amid Regulatory Uncertainty
- Rating Downgrade: JP Morgan downgraded Mereo BioPharma (MREO) from overweight to neutral due to uncertainty surrounding the regulatory outlook for setrusumab, indicating market concerns about the company's future prospects.
- Price Target Removal: The bank has removed its previous price target of $8, with MREO's stock closing at just $0.34 on March 20, reflecting a lack of investor confidence in its future profitability.
- Clinical Trial Outcomes: Analyst Priyanka Grover noted that two phase 3 trials of setrusumab missed their primary endpoint of reducing annualized fracture rate, although supportive data on bone mineral density and pain in younger patients requires further clarity on regulatory pathways and timelines.
- Funding Needs Warning: While Mereo has a cash runway into mid-2027, if a viable regulatory pathway for setrusumab is established in European markets, the company may need to raise additional capital for product launch, increasing future financing uncertainties.
See More
Mereo BioPharma Faces Class Action Lawsuit for Securities Violations
- Lawsuit Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Mereo BioPharma for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, which led to investor losses.
- Investor Damages: When the market learned that Mereo failed to meet its primary endpoints, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
- Legal Consultation: The Schall Law Firm offers free legal consultations, allowing investors to contact the firm via phone or email to discuss their rights and participate in the lawsuit.
See More
Reminder for Mereo BioPharma Class Action Participation
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while the studies failed to meet primary endpoints, leading investors to purchase ADS at inflated prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel, avoiding inexperienced intermediaries, to ensure effective legal representation and support in the class action process.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc should note that the deadline to join the class action for American Depositary Shares purchased between June 5, 2023, and December 26, 2025, is April 6, 2026, and failure to act may result in losing the opportunity to serve as lead plaintiff.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby minimizing the financial risk associated with joining the class action.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma provided misleading positive statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab, leading investors to purchase shares at artificially inflated prices, which ultimately resulted in financial losses when the true results were disclosed, highlighting significant deficiencies in the company's information disclosure practices.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has a proven track record, having recovered over $438 million for investors in 2019 alone, indicating their substantial experience and capability in handling such cases, which is crucial for investors when selecting legal representation.
See More
Faruqi & Faruqi Investigates Mereo BioPharma Securities Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities claims against Mereo BioPharma, specifically urging investors who purchased securities between June 5, 2023, and December 26, 2025, to contact them before the April 6, 2026 deadline to seek lead plaintiff status.
- Lawsuit Allegations: The lawsuit alleges that Mereo BioPharma and its executives violated federal securities laws by failing to disclose the true status of the Phase 3 ORBIT and COSMIC programs, leading to investor misconceptions about the company's prospects.
- Stock Price Plunge: On December 29, 2025, Mereo BioPharma announced that its two Phase 3 studies failed to meet primary endpoints, resulting in an 87.64% drop in stock price to $0.28 per share, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Faruq & Faruqi LLP encourages anyone with information regarding Mereo BioPharma's conduct, including whistleblowers and former employees, to contact the firm to provide legal support and share information for investor protection.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares during the class period from June 5, 2023, to December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations: The complaint alleges that Mereo BioPharma provided overly positive statements about its Phase 3 ORBIT and COSMIC programs while concealing significant adverse facts, misleading investors about the true state of these clinical trials.
- Stock Price Collapse: Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share, representing a decline of over 87.7%.
- Next Steps for Shareholders: Shareholders must register by April 6, 2026, to participate in the class action, and upon registration, they will receive updates on the case's progress without any cost or obligation to participate.
See More
JP Morgan Downgrades Mereo BioPharma Amid Regulatory Uncertainty
- Rating Downgrade: JP Morgan downgraded Mereo BioPharma (MREO) from overweight to neutral due to uncertainty surrounding the regulatory outlook for setrusumab, indicating market concerns about the company's future prospects.
- Price Target Removal: The bank has removed its previous price target of $8, with MREO's stock closing at just $0.34 on March 20, reflecting a lack of investor confidence in its future profitability.
- Clinical Trial Outcomes: Analyst Priyanka Grover noted that two phase 3 trials of setrusumab missed their primary endpoint of reducing annualized fracture rate, although supportive data on bone mineral density and pain in younger patients requires further clarity on regulatory pathways and timelines.
- Funding Needs Warning: While Mereo has a cash runway into mid-2027, if a viable regulatory pathway for setrusumab is established in European markets, the company may need to raise additional capital for product launch, increasing future financing uncertainties.
See More
Mereo BioPharma Faces Class Action Lawsuit for Securities Violations
- Lawsuit Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Mereo BioPharma for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period, which led to investor losses.
- Investor Damages: When the market learned that Mereo failed to meet its primary endpoints, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
- Legal Consultation: The Schall Law Firm offers free legal consultations, allowing investors to contact the firm via phone or email to discuss their rights and participate in the lawsuit.
See More
